Literature DB >> 28008348

Do doctors agree on doses of antipsychotic medications?

Johan Schill1, Hans Olsson2.   

Abstract

BACKGROUND: The objective of this study was to investigate the concordance in attitudes of psychiatrists towards the doses of antipsychotics given to stable outpatients with schizophrenia and to examine the psychiatrists' estimates of equally potent doses of haloperidol and olanzapine.
METHODS: We asked all 22 doctors serving at the psychiatry department of Jönköping County Hospital if they considered the combined dose of antipsychotics for 20 individual patients to be 'low', 'medium' or 'high'. We also asked each doctor to state the dose of haloperidol that they considered to be clinically equivalent to 20 mg/day of olanzapine.
RESULTS: The inter-rater reliability (Krippendorff's alpha (α)) was 0.50, and the mean estimated dose haloperidol considered clinically equivalent to 20 mg/day of olanzapine was 4.45 mg/day.
CONCLUSIONS: The inter-rater reliability (Krippendorff's α) was low, suggesting lack of agreement. The dose of antipsychotics given to a patient might thus be more influenced by which doctor they meet than the severity of the disease. The respondents in this study considered a mean dose of 4.45 mg/day of haloperidol to be clinically equivalent to 20 mg/day of olanzapine. This is a considerably lower dose than was determined by an international consensus study of antipsychotic dosing, and more in line with the available PET studies measuring central dopamine receptor blockage of optimal clinical doses.

Entities:  

Keywords:  antipsychotic agents; attitude; drug therapy; reproducibility of results; schizophrenia

Year:  2016        PMID: 28008348      PMCID: PMC5167083          DOI: 10.1177/2045125316657796

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  30 in total

1.  "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial.

Authors:  Gary Remington; Philip Seeman; Alan Feingold; Steve Mann; Chekkera Shammi; Shitij Kapur
Journal:  J Clin Psychiatry       Date:  2010-09-07       Impact factor: 4.384

Review 2.  The kappa statistic in reliability studies: use, interpretation, and sample size requirements.

Authors:  Julius Sim; Chris C Wright
Journal:  Phys Ther       Date:  2005-03

Review 3.  Modern antipsychotic drugs: a critical overview.

Authors:  David M Gardner; Ross J Baldessarini; Paul Waraich
Journal:  CMAJ       Date:  2005-06-21       Impact factor: 8.262

4.  Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

Authors:  Christoph U Correll; Anne M Frederickson; John M Kane; Peter Manu
Journal:  Schizophr Res       Date:  2006-10-27       Impact factor: 4.939

5.  The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study.

Authors:  S Kapur; R Zipursky; P Roy; C Jones; G Remington; K Reed; S Houle
Journal:  Psychopharmacology (Berl)       Date:  1997-05       Impact factor: 4.530

Review 6.  Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.

Authors:  George Foussias; Gary Remington
Journal:  Can J Psychiatry       Date:  2010-03       Impact factor: 4.356

Review 7.  Heterogeneity of treatment effects in schizophrenia.

Authors:  T Scott Stroup
Journal:  Am J Med       Date:  2007-04       Impact factor: 4.965

Review 8.  Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses.

Authors:  Gerard W K Hugenholtz; Eibert R Heerdink; Joost J Stolker; Welmoed E E Meijer; Antoine C G Egberts; Willem A Nolen
Journal:  J Clin Psychiatry       Date:  2006-06       Impact factor: 4.384

9.  Description of long-term polypharmacy among schizophrenia outpatients.

Authors:  Jaana T Suokas; Jaana M Suvisaari; Jari Haukka; Pasi Korhonen; Jari Tiihonen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-09-25       Impact factor: 4.328

10.  High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing.

Authors:  Carol Paton; Thomas R E Barnes; Mary-Rose Cavanagh; David Taylor; Paul Lelliott
Journal:  Br J Psychiatry       Date:  2008-06       Impact factor: 9.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.